ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors

Ítems similars

• Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
  per: Walker, Alec, et al.
  Publicat: (2014)
• Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
  per: Walker, Alec J., et al.
  Publicat: (2017)
• Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
  per: Tschernia, Nicholas, et al.
  Publicat: (2014)
• Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors
  per: Highfill, Steven L, et al.
  Publicat: (2013)
• Pathobiology of ALK(+) anaplastic large-cell lymphoma
  per: Amin, Hesham M., et al.
  Publicat: (2007)